NCT00165295已完成2 期
Phase II Study of Sildenafil Citrate in Waldenstrom's Macroglobulinemia
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 2
- 主要终点
- To determine response, time to progression and safety for sildenafil citrate therapy in patients with slowly progressing Waldenstrom's macroglobulinemia.
研究概览
简要总结
The purpose of this study is to determine the effects (good or bad) that sildenafil (Viagra) has on patients with slow growing Waldenstrom's macroglobulinemia (WM). Sildenafil blocks the function of several proteins necessary to the survival of certain types of cancer and laboratory tests have shown that it can destroy WM cells.
详细描述
- Sildenafil will be given orally (at home) at a reduced dose for the first week, then each week for 3 more weeks, the dose will be increased. If the patient has no major side effects, then they will receive the maximal dose for 2 years. If they have major side effects, then the dose of the drug might be lowered or the drug stopped.
- Sildenafil will be continued until their is disease progression or serious side effects.
- While patients are receiving sildenafil, they will be seen in the clinic on months 1,2,9,15 and 21 for blood tests and a subject questionnaire. They will also be seen on months 3,6,12,18 and 24 for a physical exam, blood test, physical assessment test, CT scans of chest, abdomen and pelvis, and a subject questionnaire.
- At the end of the study (month 24) a physical exam, blood tests, physical assessment test and a questionnaire will be conducted.
- Follow-up includes clinic visits at month 27,33,39 and 45 for blood tests and a questionnaire as well as visits at month 30,36,42 and 48 for physical exam, blood tests, physical assessment test, bone marrow aspirate and biopsy, CT scans of chest, abdomen and pelvis, and a questionnaire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinicopathological diagnosis of Waldenstrom's macroglobulinemia
- •Measurable disease, defined as presence of immunoglobulin M (IgM) paraprotein with a minimum IgM level of > 2 times the upper limit of each institution's normal value
- •Slowly progressing disease not requiring therapy for at least 3-6 months
- •ECOG performance status 0,1 or 2
- •Total bilirubin < 2 x ULN
- •SGOT < 3 x ULN
- •Creatinine < 2 x ULN
排除标准
- •Pregnant or breast-feeding women
- •Patients who are using organic nitrates or alpha-blockers
- •Grade III/IV cardiac problems
- •Resting hypotension (BP < 90/50) or hypertension (BP > 170/110)
- •Cardiac failure or coronary artery disease causing unstable angina
- •Evidence of left ventricular outflow obstruction
- •Impaired autonomic control of blood pressure
- •Sickle cell anemia
- •History of priapism
- •Severe and/or uncontrolled medical disease
- •Known chronic liver disease
- •Currently using ritonavir
- •History of retinal pigmentosa
结局指标
主要结局
To determine response, time to progression and safety for sildenafil citrate therapy in patients with slowly progressing Waldenstrom's macroglobulinemia.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
The Effect of Sildenafil Citrate (Viagra® (Registered Trademark)) on Brain Blood Flow in Multiple Sclerosis PatientsMultiple SclerosisNCT00094068National Institutes of Health Clinical Center (CC)76
终止
2 期
Sildenafil and Pulmonary Artery PressurePulmonary HypertensionNCT00145938University of Chicago10
已完成
4 期
Study to Evaluate Viagra's Ability to Provide a Better Sexual Experience Through Quality Erections and SatisfactionImpotenceNCT00245258Pfizer's Upjohn has merged with Mylan to form Viatris Inc.312
进行中（未招募）
1 期
The effect of Sildenafil citrate (Viagra ®) on stomach motility, gastric emptying and food intake in healthy volunteersstudy is conducted on healthy volunteers, no medical condition isinvestigatedEUCTR2011-004811-21-BEZLeuven20
招募中
不适用
Sildenafil Citrate with melatonin and intrauterine growth restrictioIntrauterine growth restriction.Disorders of newborn related to slow fetal growth and fetal malnutritionIRCT20160524028038N6Yasouj University of Medical Sciences88